Cantor Fitzgerald Issues Negative Estimate for TLSI Earnings

TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Free Report) - Research analysts at Cantor Fitzgerald lowered their FY2025 earnings estimates for TriSalus Life Sciences in a report released on Monday, May 19th. Cantor Fitzgerald analyst R. Osborn now forecasts that the company will earn ($0.90) per share for the year, down from their prior estimate of ($0.56). The consensus estimate for TriSalus Life Sciences' current full-year earnings is ($1.55) per share.

TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) last issued its quarterly earnings data on Thursday, May 15th. The company reported ($0.33) earnings per share for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.13). The business had revenue of $9.17 million for the quarter, compared to analyst estimates of $9.04 million. During the same period in the prior year, the business posted ($0.60) EPS.

TLSI has been the topic of several other reports. Canaccord Genuity Group reissued a "buy" rating and issued a $11.00 price objective on shares of TriSalus Life Sciences in a report on Friday, March 28th. Lake Street Capital began coverage on shares of TriSalus Life Sciences in a research note on Thursday, February 13th. They issued a "buy" rating and a $10.00 price target on the stock. Finally, Roth Mkm reissued a "buy" rating and issued a $11.00 price target on shares of TriSalus Life Sciences in a report on Friday, January 24th. Seven analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $10.93.

TriSalus Life Sciences Stock Up 3.7%

Shares of TriSalus Life Sciences stock opened at $5.37 on Wednesday. The firm has a market cap of $173.30 million, a PE ratio of -2.16 and a beta of 0.50. TriSalus Life Sciences has a twelve month low of $3.50 and a twelve month high of $10.10. The business has a 50-day moving average price of $5.40 and a 200 day moving average price of $5.02.

Institutional Trading of TriSalus Life Sciences

Several large investors have recently bought and sold shares of TLSI. Bank of America Corp DE raised its position in TriSalus Life Sciences by 120,471.6% in the fourth quarter. Bank of America Corp DE now owns 178,446 shares of the company's stock valued at $894,000 after purchasing an additional 178,298 shares during the period. Bridgeway Capital Management LLC increased its position in TriSalus Life Sciences by 333.3% in the 4th quarter. Bridgeway Capital Management LLC now owns 65,000 shares of the company's stock valued at $326,000 after acquiring an additional 50,000 shares during the period. Goldman Sachs Group Inc. acquired a new position in TriSalus Life Sciences during the first quarter worth $187,000. Connective Capital Management LLC purchased a new position in TriSalus Life Sciences in the fourth quarter valued at about $140,000. Finally, Renaissance Technologies LLC acquired a new stake in shares of TriSalus Life Sciences during the fourth quarter worth $67,000. Hedge funds and other institutional investors own 2.58% of the company's stock.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.